10-K.Info (Beta Test) Courtesy of Short Sands, LLC | ||||||||||||||
| ||||||||||||||
|
10-K.Info (Beta Test) Courtesy of Short Sands, LLC | |||
MERCK & CO., INC. | |||
Ticker: MRK Fiscal Year: 2010 | |||
Consolidated Statement of Cash Flows | |||
Period Ending Dec 31, 2010 10-K (Filed: Feb 28, 2011) | |||
| (In Millions, except shares in actual) | |||
| 12 Months Ended | 12 Months Ended | 12 Months Ended | |
| Dec 31, 2010 | Dec 31, 2009 | Dec 31, 2008 | |
| Cash Flows from Operating Activities | |||
| Net income | $ 982 | 13,022 | 7,932 |
| Adjustments to reconcile net income to net cash provided by operating activities: | |||
| Depreciation and amortization | 7,381 | 2,576 | 1,631 |
| In-process research and development impairment charges | 2,441 | ||
| Gains on distributions from AstraZeneca LP | (443) | (2,223) | |
| Gain related to Merck/Schering-Plough partnership | (7,530) | ||
| Gain on disposition of interest in Merial Limited | (3,163) | ||
| Equity income from affiliates | (587) | (2,235) | (2,561) |
| Dividends and distributions from equity affiliates | 324 | 1,724 | 4,290 |
| Deferred income taxes | (1,092) | 1,821 | 530 |
| Share-based compensation | 509 | 415 | 348 |
| Other | 377 | (535) | 608 |
| Net changes in assets and liabilities: | |||
| Accounts receivable | (1,089) | 165 | (889) |
| Inventories | 1,990 | 1,211 | (452) |
| Trade accounts payable | 124 | (45) | |
| Accrued and other current liabilities | 35 | (4,003) | (1,711) |
| Income taxes payable | 128 | (365) | (465) |
| Noncurrent liabilities | (98) | 231 | (108) |
| Other | (160) | 103 | (358) |
| Net Cash Provided by Operating Activities | 10,822 | 3,392 | 6,572 |
| Cash Flows from Investing Activities | |||
| Capital expenditures | (1,678) | (1,461) | (1,298) |
| Purchases of securities and other investments | (7,197) | (3,071) | (11,967) |
| Proceeds from sales of securities and other investments | 4,561 | 10,942 | 11,066 |
| Proceeds from sale of interest in Merial Limited | 4,000 | ||
| Schering-Plough merger, net of cash acquired | (12,843) | ||
| Acquisitions of businesses, net of cash acquired | (256) | (130) | |
| Distributions from AstraZeneca LP | 647 | 1,899 | |
| Decrease (Increase) in restricted assets | 276 | 5,548 | (1,630) |
| Other | 150 | 171 | 96 |
| Net Cash (Used in) Provided by Investing Activities | (3,497) | 3,156 | (1,834) |
| Cash Flows from Financing Activities | |||
| Net change in short-term borrowings | 90 | (2,422) | 1,860 |
| Proceeds from issuance of debt | 1,999 | 4,228 | |
| Payments on debt | (1,341) | (25) | (1,392) |
| Purchases of treasury stock | (1,593) | (2,725) | |
| Dividends paid to stockholders | (4,734) | (3,215) | (3,279) |
| Other dividends paid | (119) | (264) | (122) |
| Proceeds from exercise of stock options | 363 | 186 | 102 |
| Other | (106) | (126) | 33 |
| Net Cash Used in Financing Activities | (5,441) | (1,638) | (5,523) |
| Effect of Exchange Rate Changes on Cash and Cash Equivalents | (295) | 33 | (183) |
| Net Increase (Decrease) in Cash and Cash Equivalents | 1,589 | 4,943 | (968) |
| Cash and Cash Equivalents at Beginning of Year | 9,311 | 4,368 | |
| Cash and Cash Equivalents at End of Year | 10,900 | 9,311 | 4,368 |
| External Links | |
| MERCK & CO., INC. (MRK) Fiscal Year 2010 | |
| Statements of 10-K in Excel | https://www.sec.gov/.../Financial.xlxs |
| Complete 10-K in HTML | https://www.sec.gov/.../10-K.html |
| Complete 10-K in XBRL | https://www.sec.gov/.../10-K-xbrl.zip |